While the FDA has yet to take a stance on whether risk evaluation and mitigation strategy (REMS) patents can be listed in its Orange Book, the U.S. Court of Appeals for the Federal Circuit weighed in Feb. 24 with a decisive “no” when those patents only claim a system.
Actelion Pharmaceuticals Ltd. has disclosed platelet-derived growth factor receptor beta (PDGFR-β) inhibitors reported to be useful for the treatment of pulmonary arterial hypertension.
Shanghai Huilun Pharmaceutical Co. Ltd. has identified thiazle derivatives acting as dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of cancer, viral infections and autoimmune diseases.
Global Health Drug Discovery Institute (GHDDI) has presented 3C-like proteinase (3CLpro) (SARS-CoV-2) inhibitors reported to be useful for the treatment of Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 infections (COVID-19).
Eurofarma Laboratórios SA and Universidade Federal do Rio de Janeiro have synthesized N-acylhydrazone acting as sodium channel protein type 9 subunit alpha (SCN9A, Nav1.7) and/or SCN10A (Nav1.8) blockers reported to be useful for the treatment of pain.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described haloacethydrazide compounds acting as legumain (asparaginyl endopeptidase; LGMN; AEP) inhibitors reported to be useful for the treatment of subacute sclerosing panencephalitis, progressive supranuclear palsy, frontotemporal dementia and Alzheimer's disease, among others.
Shanghai Litedd Co. Ltd. has divulged 8-oxo-3-azabicyclo[3.2.1]octane compounds acting as ATR kinase inhibitors reported to be useful for the treatment of cancer.
Adlai Nortye Pharmaceutical Co. Ltd. has identified Wnt signaling inhibitors reported to be useful for the treatment of cancer, immunological and inflammatory disorders.
RSS
